EQT

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

IntegrityNext is a company based in Munich, Bayern, focused on providing a cloud-based platform for monitoring supplier sustainability and compliance. Established in April 2016 by Martin Berr-Sorokin, the platform allows businesses to automatically gather necessary supplier self-assessments and certifications while also monitoring social media for potential malpractice and reputational risks. Through its features, which include automated self-assessments, risk alerts, and a pre-built supplier questionnaire, IntegrityNext helps small and medium-sized enterprises navigate compliance data requirements set by international regulators. The platform's real-time dashboard and assessment framework enable companies to effectively manage compliance risks and streamline their processes.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

va-Q-tec is a high-tech company established in 2001, specializing in innovative insulation solutions, particularly through vacuum insulation panels (VIPs). The company's products are designed to enhance energy efficiency and are environmentally friendly, making them suitable for various applications. va-Q-tec's technology significantly reduces energy costs in diverse sectors, including the transportation of pharmaceutical products, refrigeration and freezing appliances, construction, and automotive and aerospace industries. The company operates through several segments, with a strong presence in Germany and across the European Union. Its customer base spans multiple industries, including healthcare, logistics, appliances and food, construction, and technical sectors.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

SHL Medical AG is a Swiss company based in Zug that specializes in designing, developing, and manufacturing advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989, the company serves pharmaceutical and biotechnology companies worldwide by providing comprehensive services that include final assembly, labeling, and packaging. In addition to its core focus on drug delivery systems, SHL Medical also offers contract manufacturing services and produces various medical products such as pressure mattress systems and patient lifting slings. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring it delivers innovative solutions tailored to the needs of its clients.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in the development of innovative therapeutics for cancer treatment, specifically targeting key molecular pathways involved in DNA replication stress. By focusing on these novel pathways, FoRx Therapeutics aims to create first-in-class compounds that offer a new approach to targeted anticancer therapies. Through its research and development efforts, the company seeks to provide effective solutions in the fight against cancer.

Deutsche Glasfaser Holding GmbH, founded in 2012 and based in Borken, Germany, specializes in the planning, construction, and operation of fiber optic networks, particularly targeting rural and suburban areas. As a significant player in the broadband telecommunications sector, the company aims to facilitate nationwide fiber optic expansion, contributing to Germany's digital advancement. Deutsche Glasfaser focuses on delivering fast and cost-effective fiber-to-the-home (FTTH) connections in collaboration with municipalities, positioning itself as a leader in innovative planning and construction processes. With substantial backing from experienced investors, the company has established a strong financial foundation, making it one of the most robust providers in the German market.

SHL Medical AG is a Swiss company based in Zug that specializes in designing, developing, and manufacturing advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989, the company serves pharmaceutical and biotechnology companies worldwide by providing comprehensive services that include final assembly, labeling, and packaging. In addition to its core focus on drug delivery systems, SHL Medical also offers contract manufacturing services and produces various medical products such as pressure mattress systems and patient lifting slings. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring it delivers innovative solutions tailored to the needs of its clients.

Atlantic Therapeutics Limited is a medical technology company specializing in the development and distribution of devices for pelvic floor muscle strengthening and nerve stimulation. The company offers Innovotherapy, a device that addresses these needs, as well as INNOVO, a wearable solution designed specifically for treating stress urinary incontinence, a common cause of bladder weakness. Established in 2013, Atlantic Therapeutics is headquartered in Galway, Ireland, with additional offices in London, Paris, and Salem, Germany. Its products are distributed across Ireland, the United Kingdom, France, Germany, and the Middle East. Atlantic Therapeutics operates as a subsidiary of Bio-Medical Research Limited.

SUSE is a global leader in open source solutions, providing reliable and enterprise-grade software to a diverse range of industries, including automotive, telecom, banking, healthcare, manufacturing, retail, and technology. With a strong focus on Enterprise Linux, Kubernetes Management, and Edge solutions, SUSE supports mission-critical workloads for over 60% of the Fortune 500 companies. The company emphasizes collaboration with partners and communities to empower customers to innovate across various environments, from data centers to the cloud and edge. SUSE offers consulting, blended services, and training and certification, primarily generating revenue from subscriptions. Headquartered in Nuremberg, Germany, SUSE employs nearly 2,000 people globally and derives a significant portion of its revenue from North America.

MediFox GmbH, founded in 1994 and headquartered in Hildesheim, Niedersachsen, Germany, specializes in developing software solutions for ambulatory nursing care service providers and nursing care homes. The company offers enterprise system software designed to support outpatient care services, inpatient facilities, and therapeutic practices. MediFox's software encompasses essential services such as resource and route planning, care and support documentation, management information systems, and administration services, including billing and factoring. By providing these tools, MediFox enables care providers to enhance their organizational structure and streamline their processes in response to evolving industry needs.

BBS Automation GmbH is a provider of automation solutions and engineering services, specializing in the design, development, manufacturing, and installation of automated assembly and testing systems. The company serves a diverse range of industries, including automotive, aerospace, life sciences, consumer goods, electronic devices, energy storage, and renewable energy. BBS Automation also offers leak detection, build-to-print services, and winding technology solutions, along with training and after-sales support. With nearly 550 employees, the company operates production sites in Germany, China, Malaysia, and the United States, partnering with prominent global clients. Founded in 1891 and headquartered in Garching bei München, Germany, BBS Automation is committed to delivering flexible and high-quality automation solutions for complex manufacturing and testing processes.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Studienkreis is one of Germany's largest providers of professional tutoring services, operating nearly 1,000 tuition schools nationwide since its establishment in 1974. The company specializes in providing offline and digital tutoring aimed at primary and secondary school students, offering support across all major subjects through its proprietary teaching materials and scientifically backed learning methodologies. Studienkreis focuses on helping children and adolescents enhance their academic performance and achieve consistently good grades. In addition to addressing specific academic queries, the company emphasizes fostering independent learning skills and a sense of responsibility in students, thereby improving their overall confidence in their educational journey.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

Two modern and strategically located office buildings in suburban Frankfurt.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Open Systems AG is a provider of managed security services, focusing on secure connectivity for global enterprises, non-governmental organizations, and various institutions. Founded in 1990 and headquartered in Zurich, Switzerland, with additional offices in Sydney and New York, the company specializes in a wide range of services, including network security, application delivery, identity management, and global connectivity. Their offerings encompass distributed and enterprise firewalls, WAN encryption, network security monitoring, and intrusion prevention systems. Open Systems also provides web application firewalls, email gateways, traffic shaping, and identity management solutions. The company serves multiple sectors, including government, media, finance, healthcare, infrastructure, logistics, manufacturing, and retail, ensuring comprehensive security and monitoring for critical business applications and IT networks.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

GlobalConnect is a prominent provider of fiber network, data center, and managed hosting services in Northern Europe, particularly Denmark and Germany. Founded in 1998 by Niels Zibrandtsen, the company operates an extensive optical fiber network spanning 12,500 kilometers and offers approximately 13,000 square meters of data center space. GlobalConnect delivers a range of services, including bandwidth connectivity, colocation, cloud infrastructure, and managed hosting, catering to both enterprises and consumers. With a workforce of over 200 employees, the company aims to enhance connectivity and support businesses in achieving efficient networking solutions.

CHEP is a leading global provider of supply chain solutions, specializing in enhancing efficiency and sustainability for its customers. The company offers a range of services, including asset management and repair for unit load devices (ULDs), galley carts, and ground support equipment through its CHEP Aerospace Solutions division, headquartered in Zurich, Switzerland. This division manages the world's largest independent fleet of ULDs and operates a comprehensive global network for the maintenance and repair of containers, pallets, and inflight food service equipment. By providing tailor-made outsourcing solutions, CHEP enables airlines to focus on their core operations of transporting passengers and cargo while achieving significant cost savings and operational benefits. The company serves over 80 airlines worldwide, leveraging its unique capabilities and insights to help clients improve their logistics and supply chain management.

Kuoni Reisen Holding AG is a Switzerland-based company that serves the travel industry and government sectors through three primary business activities. It operates Global Travel Distribution (GTD), which supplies hotel accommodations and destination services to travel companies and agents. The company also offers Global Travel Services (GTS), which coordinates comprehensive destination management services, including accommodation, transportation, tours, and event management. Additionally, Kuoni provides Visa Facilitation Services (VFS) through numerous application centers worldwide, assisting with visa outsourcing. The company further enhances its portfolio with Kuoni Destination Management, specializing in event development, budgeting, and creative direction, as well as providing entertainment and AV technology solutions for various events. This diverse range of services underscores Kuoni's commitment to delivering innovative and comprehensive travel and event solutions.

Apleona is an integrated real estate service provider operating primarily in the DACH region, offering a comprehensive range of services to banks, investment funds, industrial firms, and insurance companies. Established in 2016 and headquartered in Neu Isenburg, Hessen, the company specializes in technical facility services, including facility management, building technology, and interior fittings. Apleona's offerings extend to real estate management, encompassing commercial services such as letting, leasing, and marketing of properties. With a focus on enhancing performance across national borders, Apleona aims to meet the diverse needs of its clients in the real estate sector.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

kfzteile24 GmbH is a German retailer specializing in automotive spare parts and accessories, operating primarily online through its platforms www.kfzteile24.de and www.autoteile24.de. Founded in 2001 and headquartered in Berlin, the company has established itself as one of the largest online auto parts retailers in Germany, achieving significant sales growth over the years. In addition to its online presence, kfzteile24 operates three physical retail stores that are affiliated with repair shops, enhancing its service offerings. The company provides a wide range of automotive products, including exhaust systems, batteries, and braking systems, and features a vehicle selection tool that facilitates the quick identification of required parts. Customers also benefit from in-house support from automotive experts who assist in finding suitable replacement parts at competitive prices.

Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to developing innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has created a diverse pipeline leveraging proprietary technologies. The company specializes in biopharmaceutical products aimed at treating chronic diseases, focusing on sealants and orthobiologics. Its sealant product, Neuroseal, is under review for CE marking in the EU, while its orthobiologics offerings include MagnetOs Granules and MagnetOs Putty, approved for orthopedic and dental use in both the EU and the US. Kuros also has advanced clinical programs, with products like KUR-111 and KUR-113 having completed Phase II trials for bone fractures. Collaborations, such as with Checkmate Pharmaceuticals, further enhance its oncology treatment development. With its operational base in Schlieren, Switzerland, Kuros is transitioning to a commercial stage, aiming for broader market reach in key therapeutic areas.

HusCompagniet is a market leader in Denmark and rapidly growing positions in Germany and Sweden. HusCompagniet builds on a strong brand and business model, delivering high quality single-family houses with great value for money. By taking large market shares in recent years, the Company is now three times larger than the nearest competitor on the Danish market. In 2014, HusCompagniet delivered 1,010 houses to customers in Denmark, Sweden and Germany. The revenue has grown from DKK 1.2 billion in 2011 to DKK 1.8 billion in 2014. The company employs 230 people. HusCompagniet have been awarded House Builder of the Year in Denmark the last three years.

Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Evidensia Djursjukvård AB owns and operates veterinary hospitals and clinics in Sweden, Norway, Denmark, Finland, Holland, Germany, and Switzerland.

Charleston Holding is an operator of nursing homes and residential care facilities in Germany, focused on serving physically and mentally impaired residents. The company adopts a buy-and-build strategy within the nursing home market, aiming to enhance its portfolio through acquisitions. Charleston provides a range of services, including nursing care, preventative care, and intensive care, along with assisted living and daycare options. By offering these services, Charleston Holding seeks to improve the quality of life for its residents and support their well-being into old age.

Internetstores GmbH is an online retailer based in Esslingen, Germany, specializing in bicycles and outdoor products. Founded in 2003, the company operates both online and physical retail stores across Germany, Sweden, and France. It offers a diverse range of products, including bicycles, sportswear, bike parts and accessories, as well as outdoor adventure gear, camping equipment, and clothing. Internetstores caters to a wide audience, from beginner cyclists to families and hobby athletes, providing a variety of multi-brand options to enhance outdoor exploration. The company also has additional locations in Stuttgart, Berlin, Lyon, and Stockholm, and operates as a subsidiary of Signa Retail GmbH.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

United Digital Group is focused on providing businesses with digitalization strategies and branding solutions. United Digital Group provides their customers with consulting services; analytics and redesigning services for business applications; brand management solutions; and e-learning services. United Digital Group was founded by Michael Riese in 1999. It is based in Hamburg, Germany.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

AcadeMedia is the largest independent education provider in Northern Europe, offering a comprehensive range of educational services from pre-schools to adult education. The company operates approximately 550 units primarily in Sweden, Norway, and Germany. Its educational segments include preschools, compulsory schools, upper secondary schools, and adult education, with the upper secondary school segment generating the highest revenue. AcadeMedia's upper secondary school brands include Praktiska, Drottning Blanka, NTI, LBS, ProCivitas, and Rytmus. The majority of the company's revenue is derived from its operations in Sweden, reflecting its strong presence in the region's education sector.

Curetis AG, founded in 2015 and based in Holzgerlingen, Germany, develops molecular diagnostics solutions aimed at detecting infectious diseases, pathogens, and antibiotic resistance markers. The company specializes in multiparameter testing, enabling the simultaneous analysis of various analytes in a single run. Its primary focus is on providing comprehensive panels for detecting severe bacterial infections, offering rapid diagnostic solutions that help physicians obtain early and actionable insights in managing infectious diseases and antimicrobial resistance. Curetis operates as a subsidiary of OpGen, Inc. and is positioned to expand its diagnostic capabilities into other clinical applications beyond infectious diseases in the future.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

Sausalitos is a leisure restaurant chain in Germany that specializes in Californian-Mexican cuisine. It offers a diverse menu featuring breakfast, lunch, and dinner options, complemented by a selection of unique cocktails. The establishment focuses on blending exotic recipes with authentic Mexican culinary traditions, allowing customers to enjoy meals that reflect contemporary trends in gastronomy.

PharmaZell GmbH is a German company that specializes in the development and production of generic active pharmaceutical ingredients (API), controlled substances, and amino acids. Founded in 1947 and headquartered in Raubling, Germany, PharmaZell operates production facilities in Switzerland, Italy, and India, with a sales branch located in Cleveland, Ohio. The company serves the global pharmaceutical industry by providing custom synthesis, formulation development, and regulatory documentation services for both originator and generic pharmaceuticals. With a commitment to ethical practices and environmental responsibility, PharmaZell aims to be a reliable partner for its customers by offering tailored solutions and leveraging a flexible technology platform to address client needs efficiently.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Scandic Hotels Group is a Sweden-based company that engages itself in operation of hotels. It operates more than 200 hotels at close to 120 destinations which give a unique geographic reach for both corporate and leisure travelers. The majority of the company revenue comes from business travel and conferences. The business of the group is operated through various geographical region which includes Sweden, Belgium, Denmark, Finland, Norway, Poland, and Germany out of which Sweden accounts for majority of revenue.

CBR is a fashion company based in Isernhagen, Germany, specializing in women's apparel. The company produces twelve collections annually for each of its labels, enabling quick turnover and responsiveness to market demands. CBR operates both retail and outlet stores, as well as an online platform, to reach a broad customer base. Through its diverse range of fashionable clothing, CBR aims to cater to the evolving preferences of women consumers while maintaining a strong presence in the competitive fashion industry.

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.

Pfaff-silberblau's lifting and material handling business includes wire rope winches, chain hoists, rack and pinion jacks and hand pallet trucks. Its actuator business designs, develops, manufactures and markets components for lifting and motion control, including worm gear screw jacks, linear motion precision screws and quick lifting screw jacks. Based in Kissing, Germany, Pfaff-silberblau employs over 300 people and is represented worldwide through six international subsidiaries as well as numerous regional representatives.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

Metall Technologie Holding is a German manufacturer specializing in heat treatment industrial furnaces. The company produces a range of furnaces including vacuum, continuous, atmospheric, and protective gas furnaces, catering to diverse sectors such as aeronautics, automotive, medical, and steel manufacturing. Their furnaces are utilized for various heat treatment processes, including gas and oil quenching, brazing of metals, sintering, tempering, annealing, and other specialized treatments like low-pressure carburizing, nitriding, and cryogenic treatment. Metall Technologie Holding serves a global clientele that includes heat treatment contractors and equipment manufacturers, providing advanced solutions for industrial heating applications.

4-Antibody AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of antibody therapeutics with a focus on immuno-oncology. Founded in 2002, the company utilizes its proprietary Retrocyte Display technology platform to generate therapeutic antibody drug candidates from human antibody libraries expressed in mammalian B-lineage lymphocytes. In addition to providing its technology to pharmaceutical partners, 4-Antibody AG is actively developing a pipeline of preclinical checkpoint antibody programs targeting various immune checkpoints, including GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3.

Nederman Holding AB is an industrial equipment manufacturer focused on developing, producing, and marketing solutions to extract and manage hazardous substances such as fumes. The company operates through four main segments: Extraction & Filtration Technology, Process Technology, Duct & Filter Technology, and Monitoring & Control Technology. Its products aim to improve air quality, enhance sustainability, and ensure compliance with emissions regulations in industrial settings. Nederman serves a global market, with significant operations in regions such as Sweden, Germany, the UK, the US, and parts of Asia. The majority of its revenue is derived from the Extraction & Filtration Technology segment, reflecting its commitment to reducing the harmful effects of industrial processes and protecting both people and the environment.